This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
Signal Transduction and Targeted Therapy Open Access 12 January 2024
-
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Leukemia Open Access 17 October 2023
-
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
Scientific Reports Open Access 29 March 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–84.
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl J Med. 2015;373:621–31.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–22.
Taniwaki M, Yoshida M, Matsumoto Y, Shimura K, Kuroda J, Kaneko H. Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling. Mediterr J Hematol Infect Dis. 2018;10:e2018014.
Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A. Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat Immunol. 2009;10:973–80.
Guo H, Cruz-Munoz ME, Wu N, Robbins M, Veillette A. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol Cell Biol. 2015;35:41–51.
Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120:552–9.
Postelnek J, Neely RJ, Robbins MD, Gleason CR, Peterson JE, Piccoli SP. Development and validation of electrochemiluminescence assays to measure free and total sSLAMF7 in human serum in the absence and presence of elotuzumab. AAPS J. 2016;18:989–99.
Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, et al. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia. 2020;34:180–95.
Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, et al. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Int J Hematol. 2020;111:65–74.
Acknowledgements
This study was funded by Bristol-Myers Squibb K.K. English editing and formatting for journal submission was supported by Caudex, funded by Bristol-Myers Squibb K.K.
Author information
Authors and Affiliations
Contributions
AS prepared manuscript; AS, SK, and MM collected and analyzed data from CA204-116 study; MH, KS, and KO contributed CA204-116 study execution and data analysis, and YF supported and directed sSLAMF7 analysis.
Corresponding author
Ethics declarations
Conflict of interest
AS, SK, and MM are employees of Bristol-Myers Squibb K.K. MH reports postmarketing surveillance study fees from Celgene, Fujifilm RI Pharma, and Shire Japan. KS reports personal fees from Bristol-Myers Squibb K.K., Celgene, Janssen Pharmaceutical, Novartis, Sanofi, and Takeda. YF is supported by Grant-in-Aid for Scientific Research from JSPS, Ministry of Education, Culture, Sports, Science and Technology-supported program for the Strategic Foundation at Private Universities, Japan Leukemia Research Fund, Yasuda Memorial Cancer Foundation, Novartis Foundation, and Takeda Foundation. KO reports honoraria from Bristol-Myers Squibb K.K., Celgene K.K., Janssen Pharmaceutical K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd, and Takeda Pharmaceutical Co. Ltd.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Suzuki, A., Kakugawa, S., Miyoshi, M. et al. Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia 34, 3088–3090 (2020). https://doi.org/10.1038/s41375-020-0860-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0860-7
This article is cited by
-
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
Signal Transduction and Targeted Therapy (2024)
-
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Leukemia (2024)
-
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
Scientific Reports (2023)